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Summary The pharmacological interest in lonidamine is related to its ability to enhance the cytotoxic effects of several DNA-damaging anti-
tumour agents. This study was undertaken to better understand the in vivo interaction between lonidamine and cisplatin in the treatment of
human tumour xenografts, including three carcinoma models characterized by a different responsiveness to cisplatin, in spite of the presence
of a wild-type p53 gene in all tumours. The drug combination was more effective in tumour growth inhibition than cisplatin alone against
MX-1 breast carcinoma and A2780 ovarian carcinoma, both highly responsive to cisplatin, whereas no influence of lonidamine was observed
on anti-tumour activity of cisplatin in the treatment of the relatively resistant IGROV-1 ovarian carcinoma. As cisplatin activity is related to
induction of apoptosis, the modulation of drug-induced apoptosis by lonidamine was investigated. Under conditions in which lonidamine itself
had negligible effects on tumour growth and apoptosis, the modulating agent stimulated the apoptotic response induced by cisplatin in the
responsive but not in the resistant tumours. Tumour response was dependent not only on the drug activation of apoptosis, but mainly on the
persistence over time of the event. In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the
efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. Lonidamine itself caused
a delayed phosphorylation of bcl-2. These results are consistent with the interpretation that lonidamine is effective in modulating biochemical
factors involved in regulation of apoptosis.
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Lonidamine (LND) is a dichlorinated derivative of indazole-3-
carboxylic acid, which has been described as an inhibitor of
energy metabolism (Silvestrini, 1991). A selective action of LND
on tumour cells has been attributed to its inhibitory effect on mito-
chondria-bound hexokinase, which is present in tumour cells but
not in normal differentiated cells (Hume and Weidemann, 1979;
Floridi et al, 1981). Studies on different tumour cell lines have
shown increased cytotoxic efficacy of DNA-damaging anti-
tumour drugs when combined to LND (Chitnis and Adwankar,
1986; Zupi et al, 1986; Raaphorst et al, 1990; Teicher et al, 1991;
Zaffaroni et al, 1994). In the human MX-1 mammary tumour
xenografted in nude mice, we recently demonstrated a therapeutic
advantage for LND combined to cisplatin (Pratesi et al, 1996). The
cellular and molecular basis ofthe interaction remains to be deter-
mined. At the cellular level, the synergism could be related to a
specific interference of LND with energy-dependent DNA-repair
processes subsequent to cisplatin-induced DNA damage (Hahn et
al, 1984). Such an effect could result in a fixation ofDNA damage,
thus activating a cascade ofbiochemical events, possibly resulting
in cell death by apoptosis. Indeed, apoptosis is a major mode of
Received 19 March 1997
Revised 3 July 1997
Accepted 8 July 1997
Correspondence to: G Pratesi, Istituto Nazionale Tumori, Via Venezian 1,
20133 Milan, Italy
cell death in response to DNA-damaging treatment (Kerr et al,
1994), and a correlation between apoptotic death and tumour
sensitivity to drugs has been documented in some in vitro systems
(Wu and El-Deiry, 1996). We recently reported that human ovarian
cancer cell lines selected for resistance to cisplatin have reduced
susceptibility to apoptosis induction after cytotoxic treatment, as a
consequence of loss of wild-type p53 function (Perego et al,
1996). A correlation between apoptosis and cellular sensitivity has
also been documented for LND, but LND-induced apoptosis is not
mediated by thep53 gene (Del Bufalo et al, 1996).
The aim ofthe present study was to investigate further the inter-
action of LND and cisplatin in human carcinoma systems charac-
terized by different responsiveness to cisplatin. One relatively
resistant (the ovarian IGROV-1) and two sensitive (the ovarian
A2780 and the mammary MX-1) carcinomas were used. All
tumours, maintained by serial passages in nude female athymic
mice, were characterized by wild-type p53 (Perego et al, 1996;
Arcamone et al, 1997; Caserini et al, 1997). In particular, the study
investigated the effect of drug treatment on tumour apoptosis
induction and its correlation to tumour response. The results ofour
study showed that LND, under conditions in which alone it had a
negligible effect, potentiated cisplatin efficacy only in tumours
highly responsive to cisplatin and that, in these sensitive tumour
systems, LND enhanced the apoptotic response induced by treat-
ment with the cytotoxic agent and maintained it for a long time.
Moreover, our results show that both cisplatin and LND induce
phosphorylation ofbcl-2 protein.
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Table 1 Influence of LND on anti-tumour activity of cisplatin in human tumour xenograftsa
Tumour Drug Dose (mg kg-') Treatment TVI%b LCKc ToxlTotd
Route Schedule
MX-1 LND 50 i.p. qdx2O 33 (39) 0.2 0/5
Cisplatin 6 i.p. Single treatment 99 (33) 3.4 0/5
Cisplatin + LND 6 + 50 100 (39) > 7.3 0/5
A2780 LND 50 i.p. qdx2O 51 (20) 0.5 3/5
Cisplatin 6 i.p. Single treatment 65 (17) 0.5 0/5
Cisplatin + LND 6 + 50 78* (20) 1.3 2/5
LND 100 p.o. qdx5/wx3w 10 (26) 0 0/5
Cisplatin 6 i.v. q7dx3 90 (26) 2.0 0/5
Cisplatin+LND 6 + 100 97* (26) 2.8 1/5
IGROV-1 LND 50 i.p. qdx2O 17 (28) 0 1/5
Cisplatin 6 i.p. Single treatment 32 (21) 0.1 0/5
Cisplatin+LND 6 + 50 45 (28) 0.3 1/5
LND 100 p.o. qdx5/wx3w 45 (30) 0.9 0/4
Cisplatin 6 i.v. q7dx3 56 (30) 1.1 1/5
Cisplatin+LND 6 + 100 56 (30) 1.0 0/5
aLND treatment started immediately after each cisplatin injection. bThe highest inhibition of tumour volume is reported; in parentheses the day on which it was
evaluated. cLog10 cell kill calculated by assessing the difference in mean time required for tumours of treated and control mice to reach 1000 or 2000 mm3 and
dividing that value by the product of 3.32 and tumour doubling time. dToxic deaths/total no. of mice. All mice were cured in this group. *P< 0.05 vs cisplatin-
treated tumours.
MATERIALS AND METHODS
Animals
Six- to 10-week-old female athymic nude CD-1 mice were used in
the study. Animals (obtained from Charles River, Calco, Italy) were
maintained in laminar air-flow rooms. Sterilized cages, bedding
and acidified water were used for mice care. The air was condi-
tioned at a temperature of 24-26'C and 50% humidity. The experi-
ments were approved by the Ethics Committee of our Institute,
according to UKCCCR guidelines (Workman et al, 1988).
Tumours
The MX-I human breast tumour line, from an infiltrating duct cell
breast carcinoma of an untreated patient, was established s.c. in
nude mice in the National Cancer Institute (NCI, Bethesda, MD,
USA). A2780 and IGROV-l cell lines were derived from ovarian
carcinomas of untreated patients. The A2780 and IGROV- 1
human tumour lines were established s.c. in nude mice, from the
respective cell lines, in the Istituto Nazionale per lo Studio e la
Cura dei Tumori, Milan. For in vivo line maintenance and experi-
mental purposes, tumour specimens were grafted s.c. in both
flanks of mice by a 13-gauge trocar. Growth of s.c. tumours was
followed by biweekly calliper measurements of length and width.
Tumour volume (TV) was calculated using the formula: TV =
mm3 = width x width x length/2 (Geran et al, 1972). Tumour
doubling time was calculated for each tumour line from the semi-
logarithmic best-fit curve of each control tumour plotted vs time,
from the day on which the tumour became measurable until the
day on which the curve began to level off (exponential phase of
growth). The pattern of lactic dehydrogenase human isoenzymes
could be detected persistently in tumour extracts.
Chemotherapy studies
Cisplatin (kindly supplied by Pharmacia Upjohn, Milan, Italy) was
dissolved in saline and LND (kindly supplied by Angelini, Rome,
Italy) was dissolved in 2.3% N-methyl-D-glucamine (NMG,
Aldrich) water solution; 10 mg ofLND was previously dissolved in
0.3 ml of the NMG solution and then diluted in sterile distilled
water. Both drugs were given in a volume of 10 mg kg-' of body
weight. Each experimental group consisted of at least eight assess-
able tumours. Control mice were treated with the NMG solution
according to the same route and schedule used forLND in the same
experiment. Tumour-bearing mice were treated according to two
schedules: (a) single i.p. cisplatin treatment followed by 20 daily
LND treatments (50 mg kg-') according to the same route and (b)
three i.v. cisplatin injections, once a week for 3 consecutive weeks,
each one followed by five administrations of LND per os
(100 mg kg-'). The same dose ofcisplatin, 6 mg kg-' per injection,
was used in the two schedules. A LND dose of50 mg kg-' i.p. and
100 mg kg-' per os had similar efficacy in our previous study
(Pratesi et al, 1996). In both schedules, LND was delivered after
cisplatin treatment because this drug sequence was found to be the
optimal one for the combination (Cividali et al, 1992).
Drug activity was assessed as: (a) the percentage of tumour
volume inhibition (TVI%), calculated by the formula: TVI% =
l00-(tV/cVxlOO), where tV is the mean TV of treated tumours
and cV that of control tumours (the day on which TVI% was
calculated is reported in Table 1); (b) the log,0 cell kill achieved by
the drug treatment, according to the formula: T - C/DT x 3.32,
where T is the mean time (days) required for the treated tumours
and C the mean time for the control tumours to reach an estab-
lished volume (see Table 1) and DT is the doubling time ofcontrol
tumours. A tumour was considered responsive when the drug
treatment achieved aloglocell kill > 1.
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Figure 1 Time course of apoptosis induction in human MX-1, A2780 and IGROV-1 tumour xenografts, treated with: 10 mg kg-' of cisplatin (E, i.p. single
injection at day 0); 100 mg kg-' of LND (0, p.o. daily from day 0); or cisplatin + LND (-). A, Untreated controls. Mice were killed at the indicated times, tumours
were removed immediately and processed as indicated in Materials and methods. Determination of the apoptotic index was assessed at the selected time
points. For each time point two tumours were examined. Using a light microscope at x400 magnification, the mean number of cells per field for each tumour
model was assessed examining ten randomly chosen fields (277, 358 and 379 cells per field for MX-1, A2780 and IGROV-1 respectively). Ten fields of non-
necrotic areas were selected in each section, in each field the number of apoptotic nuclei was recorded, and the apoptotic index is expressed as percentage of
apoptotic nuclei relative to the mean number of cells per field. Mean values are reported. Standard error never exceeded 0.65
Deaths occurring in treated mice before the death of the first
control mouse were ascribed to toxic effects.
Determination of mitotic and apoptotic indexes
Tumour-bearing mice were treated with cisplatin and LND, alone
or in combination. Cisplatin was given as a single i.p. injection at
the dose of 10 mg kg-1 (which is slightly below the maximum-
tolerated dose of 12 mg kg-' in our strain of mice); LND
(100 mg kg-') was administered orally and daily, startingjust after
the cisplatin injection. At sequential times after the cisplatin injec-
tion (from 1 day on), one mouse per group was sacrificed by
cervical dislocation; its two tumours were removed, placed in
neutral-buffered formalin and processed for embedding in paraffin
blocks. From each tumour block, 2- to 4-micron sections were cut
and adhered to poly-L-lysine pretreated slides. Tissue sections
were then treated according to the method described by Gavrieli et
al (1992). For the TdT-mediated dUTP nick-end labelling
(TUNEL) reaction, the in situ cell death detection POD kit
(Boehringer Mannheim, Ingelheim, Germany) was used. The final
staining was performed using a DAB (Sigma, St Louis, MO, USA)
solution. Sections were counterstained with haematoxylin.
Apoptotic index (AI) was determined as indicated in the figure
legends, using a light microscope at 400 x magnification.
Successive sections ofthe same tumour samples were stained with
the standard haematoxylin-eosin method to determine the mitotic
index (MI), which is expressed as for the Al. Scoring of histolog-
ical tumour sections was conducted without knowledge of the
results ofthe tumour growth-inhibition studies.
Western blot analysis
Tumour samples were minced and suspended in 500,l of
Laemmli buffer (Laemmli, 1970); suspensions were completely
disrupted using a tissue Potter and successively sonicated for
1 min at low intensity. Debris was sedimented at 12 000 r.p.m. for
10 min at 4°C. Supematants containing protein extracts were
collected, and a 1:10 volume of P-mercaptoethanol was added;
they were then boiled for 3 min and stored at -80°C. Protein
concentration was determined using the BCA Protein Assay
Reagent (Pierce, Rockford, IL USA). Aliquots of 80 gg were size-
separated by SDS-PAGE (12% gel) and transferred to a nitro-
cellulose filter (BioRad Lab, Segrate, Italy) by electroblotting.
Immunodetection was carried out using an anti-bcl-2 (Santa Cruz
Biotechnology, Segrate, Italy) polyclonal antibody (1:1000), and
blots were successively developed with peroxidase anti-rabbit
antibody (1:2000) using the enhanced chemiluminescence (ECL)
detection kit (Amersham, Little Chalfont, UK). The phosphoryl-
ated form of bcl-2 protein was detected as a slower mobility form
as previously described (Haldar et al, 1995).
Statistical analysis
The statistical significance of the differences in tumour volumes
and Al values between cisplatin- and cisplatin + LND-treated
tumours was tested using the Student's t-test (two-tailed). P-values
were considered to be significant when less than or equal to 0.05.
RESULTS
Chemotherapy studies
The influence of LND on cisplatin anti-tumour efficacy in human
tumour xenografts is reported in Table 1. The MX-1 tumour was
very sensitive to cisplatin treatment, as tumours treated with a
single suboptimal dose disappeared by day 15. However, some
tumours regrew after40-50days (Pratesi et al, 1996). The enhance-
ment induced by LND on this tumour was dramatic, as all mice
were cured by the combination (no tumour regrowth up to 100
days). A significant enhancement of cisplatin anti-tumour activity
by LND was achieved also in A2780 tumour-bearing mice, using
either treatment schedules. As expected, in this sensitive tumour,
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Table 2 Effect of cisplatin and the cisplatin + lonidamine combination on apoptosis in human carcinoma xenografts
Mitosis Apoptosis
Tumour line (type) DTa (days) Basalb Basalb Peakc (day)
Cisplatin Cisplatin + LND
MX-1 (mammary) 6.3 ± 0.9 3.4 ± 0.6 0.4 ± 0.2 4.35 (10) 6 (10)
A2780 (ovarian) 2.4±0.5 0.8±0.18 1.4±0.2 10.95 (1) 18.1 (6)
IGROV-1 (ovarian) 4.9±1.1 0.7±0.2 1.8±0.5 3.7 (1) 3.4 (1)
aDoubling time (DT) was determined in untreated control tumours. Mean values ± s.d. are shown. bThe basal level of mitosis and apoptosis was determined
from all untreated control tumours. Mean values ± s.d. are shown. cThe peak level of apoptosis was determined from the time course of treated tumours and is
defined as the highest Al value observed within the observation time. In parentheses, the day at which the peak was detected.
A
...
B
1bI-2
Figure 2 Western blot analysis of bcl-2 protein in human MX-1 tumour.
Tumour-bearing mice were treated with 10 mg kg-' of cisplatin (day 0, i.v.;
lane 2), cisplatin + LND (lane 3), 100 mg kg-' of LND (p.o. daily from day 0;
lane 4) or were untreated (lane 1). Five (A) and 10 days (B) after cisplatin
treatment, tumours were excised and processed as described in Materials
and methods. Equal amounts of protein were loaded. Arrows, modified
(phosphorylated) form of bcl-2 protein
cisplatin activity was higher when the optimal dose (6 mg kg-' for
three times) instead of a suboptimal one (6 mg kg-', single treat-
ment) was administered to mice. Conversely, only a marginal
increase of drug efficacy was observed in the naturally resistant
IGROV-1 tumour between one and three cisplatin treatments, nor
did LND influence the low anti-tumour activity. LND was better
tolerated after oral administration than i.p. treatment.
Induction of apoptosis
The kinetics ofapoptosis induction by drug treatment was studied
in tumour tissues, and the time course and the extent of apoptosis
induction in the three tumour lines is reported in Figure 1.
Established MX-1 tumours (450-mm3 mean volume) were treated
with 10 mg kg-' ofcisplatin, and the Al was calculated in histolog-
ical sections of tumours at sequential times (from day 1 to day 12
after treatment). In cisplatin-treated tumours, the percentage of
apoptotic cells was similar to that of untreated controls on day 1
and rose to high values from day 5 onwards. The Al in tumours
treated with cisplatin + LND (given daily) followed the same
kinetics as that of cisplatin-treated tumours but was generally
higher (most evident on day 10). The increase in Al of treated
tumours was persistent, as the Al was still higher than that
of control tumours on the last day of observation (day 12). No
evaluation could be made at longer times for tumour disappear-
ance. Untreated control tumours presented a low Al (basal level
0.4 ± 0.2), which remained unchanged up to day 12. LND alone
did not modify the Al compared with untreated controls.
Mice bearing A2780 tumours were treated when tumour volume
was around 350 mm3. Spontaneous tumour apoptosis was higher
(basal level 1.4 ± 0.2) than that in MX-1 tumours. Again, LND
alone was ineffective as an apoptosis inducer at all times. In
cisplatin-treated tumours, a prompt increase in Al had already been
induced at 1 day after treatment, but values returned to basal levels
by day 6. Conversely, in the cisplatin + LND-treated tumours the
high level of Al lasted much longer, and the level at day 6 was
significantly different between the two groups (P < 0.001).
In IGROV-1 tumour-bearing mice, treated when tumours were
about 200 mm3, basal apoptosis values were the highest among the
three tumours tested (basal level 1.8 ± 0.5). In spite oftumour cell
ability to activate spontaneous apoptosis, cisplatin treatment only
marginally increased the Al (less than twofold) and only for a
short time (peak level on day 1). Moreover, the Al in tumours
treated with the cisplatin + LND combination never exceeded the
values ofcisplatin-treated tumours.
Table 2 summarizes the apoptotic and mitotic levels in the three
tumour lines investigated in the study. Mitosis level differed in the
tumours and did not correlate with tumour doubling time. The
MX-1 tumour, which has the highest MI, was also the most
responsive tumour to cisplatin treatment. Considering the
apoptosis level induced by cisplatin treatment, it is noteworthy that
the very sensitive MX-1 tumour cells keep dying from apoptosis
for long time (the Al was still higher than in control tumours after
12 days). Moreover, the duration ofapoptosis correlated well with
tumour response to treatment. Comparing the time course of
apoptosis in MX-1 and A2780 tumours, the influence of LND on
apoptosis induced by cisplatin appeared to be related more to
maintenance than to the peak level ofthe apoptotic event.
Bcl-2 expression and modulation
Although all three tumours were characterized by a wild typep53,
only MX-1 overexpressed bcl-2 protein. Thus, only in this tumour
model, modulation of the anti-apoptic protein was studied after
treatment with cisplatin (single i.v. 10 mg kg-') and/or LND (daily
per os, 100 mg kg-1). Five and 10 days after cisplatin treatment
(day 0), one mouse per group was sacrificed and its two tumours
were excised and processed for Western blot analysis of bcl-2
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protein (Figure 2). At 5 days, cisplatin and cisplatin + LND treat-
ments induced phosphorylation of the protein. This change was
associated with an increased expression of bax protein (not
shown). Meanwhile, a progressive down-regulation of bcl-2
protein was observed in both groups, which was almost complete
at 10 days. Again, a parallel reduction of bax level was detected
at this time (not shown). LND alone induced an appreciable
increase of the phosphorylated form of bcl-2, which was more
evident at 10 days.
DISCUSSION
Our earlier studies on LND as a modulator of anti-tumour activity
of cytotoxic agents showed that improvement of the therapeutic
efficacy is related to responsiveness of the tumour to the drug used
in combination with LND (Pratesi et al, 1996). Indeed, using a
breast carcinoma model, MX- 1, which is responsive to cisplatin
but resistant to doxorubicin, LND was able to potentiate the
activity of cisplatin but exhibited negligible effects on tumour
response to doxorubicin treatment. In an attempt to better under-
stand the mechanisms of the enhancement of cisplatin activity in
combination with LND, in the present study we extended the
investigation to other tumour systems characterized by different
tumour responsiveness to cisplatin. Indeed, a synergistic interac-
tion between cisplatin and LND was observed in the two cisplatin-
responsive tumours (i.e. MX-1 breast carcinoma and A2780
ovarian carcinoma) but not in the relatively resistant IGROV-1
ovarian carcinoma. The present results are consistent with the
interpretation that the nature of the drug interaction is dependent
on the intrinsic tumour cell sensitivity to the cytotoxic agent.
Based on this preclinical study, when used in combination with
cisplatin, LND should be regarded as a potentiating agent rather
than as a modulator of drug resistance (Calabresi et al, 1994).
As, in our experience, tumour responsiveness reflects, at least
in part, drug ability to activate an apoptotic response, this study
focused on apoptosis induction as a cellular basis ofcytotoxic drug
potentiation by LND. Previous studies have indicated that p53
gene status is an important determinant of cellular sensitivity to
cisplatin (Rusch et al, 1995; Perego et al, 1996; Righetti et al,
1996). For this reason, only tumour models characterized by wild
type p53 were chosen for the study. The responsiveness of MX-1
and A2780 tumours is consistent with p53 gene status. The
marginal activity of cisplatin in the treatment of IGROV-1 tumour
reflects a relative in vitro resistance of the IGROV-1 cells
(Caserini et al, 1997). The molecular basis of the limited respon-
siveness of the IGROV-1 tumour is probably related to defence
mechanisms (e.g. increased efficiency of the glutathione-depen-
dent system) (Pratesi et al, 1995) rather than an intrinsic resistance
to apoptosis activation, as a marked apoptotic response could be
achieved after in vitro exposure to cytotoxic levels of DNA-
damaging agents (Perego et al, 1996). This interpretation is consis-
tent with the finding that IGROV-1 cells displayed a significant
basal level of apoptosis (Table 2). In the responsive tumour
systems, the pattern of apoptosis induction could account for the
differential tumour sensitivity to cisplatin. In the A2780 tumour, a
marked and prompt apoptosis induction was observed; however,
the drug-induced effect was transient. Thus, multiple treatments
are required to achieve a therapeutic efficacy similar to that
produced by a single dose ofcisplatin in the hypersensitive tumour
MX-1; conversely, in this tumour, apoptosis induced by cisplatin
was delayed but very persistent. The very low basal level of
apoptosis could reflect the overexpression of the anti-apoptotic
protein bcl-2. However, no correlation has been found between
bcl-2 levels and response to cisplatin among the tumours tested.
In contrast to cellular response to cisplatin, apoptosis induced in
vitro by LND is independent ofthep53 gene, as expected for a non-
DNA-damaging agent (Del Bufalo et al, 1996). Based on these
observations, a cooperation between p53-dependent and p53-inde-
pendent apoptotic pathways could account for the synergistic inter-
action between cisplatin and LND, in terms of tumour growth
inhibition and apoptosis induction. In the IGROV-1 tumour, the
marginal induction of apoptosis by cisplatin could not achieve
the threshold required for an efficient interaction, as LND itself
at the dose level used in vivo was not effective as an
apoptotic inducer. In contrast, LND-induced biochemical changes,
although not resulting in apoptosis, could be relevant in tumour
systems in which a marked apoptosis was activated by the DNA-
damaging treatment. As a persistent induction of apoptosis was
correlated with anti-tumour drug efficacy, it is probable that the
daily administration of LND favours activation of the apoptotic
process, which appears to be differentially regulated in the respon-
sive tumours but not in the resistant IGROV-I. This interpretation
is consistent with the observation that phosphorylation of bcl-2 was
a late event after multiple LND treatments. A role of bcl-2 has been
implicated in the tumour cell susceptibility to apoptosis (Reed,
1994). Our study provides evidence that in the MX- I tumour the
efficacy of cisplatin treatment was related to phosphorylation of
bcl-2 followed by down-regulation. Phosphorylation was enhanced
by LND, and this might represent a basis of the synergistic inter-
action between cisplatin and LND. A marked modulation of bcl-2
by a DNA-damaging agent was an unexpected finding, as no phos-
phorylation was detected in prostatic tumour cells treated for 24 h
with cisplatin (Haldar et al, 1997). A possible explanation for this
discrepancy is that, in contrast to taxol, phosphorylation induced by
the DNA-damaging agent is a late event. Indeed, in our in vivo
experiments, bcl-2 modulation was found 5-10 days after drug
treatment. Our finding that LND itself induced bcl-2 phosphory-
latin suggests that the drug may potentiate the cisplatin-induced
apoptosis through a mechanism involving inactivation of bcl-2
function and provides new insights into the mechanism ofaction of
LND as an anti-tumour chemotherapy modulator. LND is known to
interfere with mitochondria functions (Hume and Weidemann,
1979; Floridi et al, 1981; Sarti et al, 1994) and to alter the outer
mitochondrial membrane (Sarti et al, 1994). Our observations on
MX-1 tumour raise the possibility that LND action is mediated by
interfering with bcl-2 membrane-stabilizing effect on mitochon-
dria, which is considered critical in the bcl-2 anti-apoptotic role
(Kroemer, 1997).
In conclusion, the present study showed that LND may act as a
potentiating agent ofcisplatin anti-tumour efficacy, possibly stimu-
lating the apoptotic response induced by the DNA-damaging drug
in responsive tumours. Moreover, the combination may produce
particularly favourable results in bcl-2-overexpressing tumours.
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